Ara-290
ypical Dosing Protocols (Research/Compounded Use Only) – Ara-290 (Cibinetide)
Common protocol: 2–4 mg subcutaneously once daily for 28 consecutive days (most clinical trials used 4 mg daily). Some protocols begin with 2 mg daily for the first week then increase to 4 mg.
Other reported ranges:
Standard research/wellness: 2–4 mg daily
Higher: Up to 6–8 mg daily in some exploratory settings (less common)
Frequency: Once daily (often in the morning); cycles typically 28 days (4 weeks), with some extending to 6–12 weeks depending on goals. Repeat cycles after a break are sometimes used.
Reconstitution example (for a typical 16 mg vial, common research size): Add 2 mL bacteriostatic water(yielding 8 mg/mL).
2 mg = 0.25 mL (25 units on U-100 insulin syringe)
4 mg = 0.5 mL (50 units)
Administration: Subcutaneous injection (abdomen or thigh). Rotate injection sites.
Dosing is highly individualized based on goals (neuropathy support, inflammation, tissue repair) and response—consult a qualified healthcare provider experienced with peptides for personalized guidance. This is for informational purposes only.
Key Potential Benefits of Ara-290
Significant Reduction in Neuropathic Pain and Allodynia
Rapidly reduces mechanical and cold allodynia (heightened pain sensitivity) in preclinical nerve injury models, with dose-dependent relief that can persist long-term through suppression of spinal microglia activation and central inflammatory responses.
Improves neuropathic symptom scores (e.g., via PainDetect questionnaire and Small Fiber Neuropathy Screening List) in clinical studies, with notable pain reduction in sarcoidosis-associated small fiber neuropathy (SFN) and diabetic neuropathy patients.
Enhances overall pain management and sensory function, contributing to better daily comfort and reduced hypersensitivity in chronic neuropathic conditions.
Promotion of Small Nerve Fiber Regeneration and Repair
Increases corneal nerve fiber density (CNFD) and supports regrowth of small nerve fibers in clinical evaluations (e.g., after 28 days of treatment in sarcoidosis patients), demonstrating structural regenerative effects beyond symptom relief.
Improves nerve morphology, conduction, and axonal survival in preclinical diabetic and injury models, while aiding remyelination and counteracting nerve degeneration.
Facilitates neuronal protection and differentiation, supporting recovery of small fiber function in skin, cornea, and peripheral nerves.
Potent Anti-Inflammatory and Tissue-Protective Effects
Activates the innate repair receptor to suppress pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) and pathways like NLRP3 inflammasome while promoting cytoprotective and healing signals without broad immune suppression.
Reduces neuroinflammation, oxidative stress, and tissue damage in models of ischemia-reperfusion, hypoxia, and chronic inflammation, shifting the environment toward repair and resolution.
Supports broader anti-inflammatory benefits in autoimmune or inflammatory models (e.g., experimental autoimmune encephalomyelitis), contributing to reduced disease severity and tissue preservation.
Improved Metabolic Control and Glycemic Parameters
Enhances hemoglobin A1c (HbA1c) levels and lipid profiles in Phase 2 studies of type 2 diabetes patients with painful neuropathy, supporting better overall glucose regulation and metabolic balance.
Aids insulin sensitivity and metabolic efficiency through tissue-protective mechanisms, with observed improvements in metabolic markers over treatment periods (e.g., 56 days).
Contributes to favorable body composition and energy-related outcomes by mitigating metabolic stress and inflammation in diabetic or obese models.
Enhanced Microcirculation, Wound Healing, and Organ Protection
Improves microvascular function, endothelial health, and tissue perfusion, offering potential support for peripheral vascular issues, wound healing, and recovery from ischemic injury (including renal and cardiac models).
Protects against apoptosis and structural damage in organs under stress (e.g., kidney ischemia-reperfusion), while promoting faster functional recovery and reduced fibrosis.
Demonstrates exploratory benefits in models of cardiac stress (preserving ejection fraction and systolic function) and other tissues requiring repair.
Broader Neuroprotective and Quality-of-Life Advantages
Provides neuroprotection in models of neurodegeneration, traumatic brain injury, and conditions like Alzheimer’s-like pathology by modulating monocyte behavior, reducing inflammation, and supporting brain resilience.
Improves quality-of-life measures, including physical functioning, pain dimensions (SF-36), and autonomic symptoms, leading to enhanced daily vitality and well-being in neuropathy patients.
Offers a non-erythropoietic alternative to EPO with targeted cytoprotective actions, enabling potential use across neuropathic, inflammatory, and metabolic challenges without hematopoietic side effects.
